[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100610453":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":24,"centralContacts":28,"locations":37,"responsibleParty":69,"collaborators":73,"id":85,"slug":86,"hasResults":87,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":18,"eligibilityCriteria":91,"healthyVolunteers":87,"sex":92,"minAge":93,"maxAge":18,"enrollmentInfo":94,"targetDuration":18,"studyType":97,"phases":98,"briefSummary":100,"conditions":101,"keywords":18,"overallStatus":40,"whyStopped":18,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":110,"completionDateStruct":111,"leadSponsor":113,"locationsCount":114},{"fullName":5,"class":6},"University of Minnesota","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"BPaLMZ Regimen","EXPERIMENTAL","bedaquiline, pretomanid, linezolid, moxifloxacin, and pyrazinamide (BPaLMZ)",[13],"Drug: BPaLMZ Regimen",{"label":15,"type":16,"description":17,"interventionNames":18},"Standard of Care Regimen","NO_INTERVENTION","rifampicin, isoniazid, pyrazinamide, ethambutol (RHZE) therapy",null,[20],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":18},"DRUG","bedaquiline, pretomanid, linezolid, moxifloxacin, and pyrazinamide",[9],[25],{"name":26,"affiliation":5,"role":27},"David Boulware, MD","PRINCIPAL_INVESTIGATOR",[29,33],{"name":26,"role":30,"phone":31,"phoneExt":18,"email":32},"CONTACT","612-624-9996","coat.trial@gmail.com",{"name":34,"role":30,"phone":35,"phoneExt":18,"email":36},"Darlisha Williams, MPH","612-624-0469","will1223@umn.edu",[38,56],{"facility":39,"status":40,"city":41,"state":18,"zip":18,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Infectious Diseases Institute","RECRUITING","Kampala","Uganda","UG",{"type":45,"coordinates":46},"Point",[47,48],32.58219,0.31628,{"lat":48,"lon":47},[51,54],{"name":52,"role":30,"phone":18,"phoneExt":18,"email":53},"Suzan Namombwe, MBChB","snamombwe@idi.co.ug",{"name":55,"role":27,"phone":18,"phoneExt":18,"email":18},"David B Meya, MBChB, MMed, PhD",{"facility":57,"status":40,"city":58,"state":18,"zip":18,"country":42,"countryCode":43,"cosmosGeoPoint":59,"geoPoint":63,"contacts":64},"Mbarara University of Science and Technology","Mbarara",{"type":45,"coordinates":60},[61,62],30.64851,-0.60467,{"lat":62,"lon":61},[65],{"name":66,"role":30,"phone":67,"phoneExt":18,"email":68},"Conrad Muzoora, MBChB MMed","256772547175","conradmuzoora@gmail.com",{"type":70,"investigatorFullName":71,"investigatorTitle":72,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"SPONSOR_INVESTIGATOR","David Boulware","McKnight Distinguished Professor",[74,76,77,79,80,82],{"name":75,"class":6},"Infectious Diseases Institute, Uganda",{"name":5,"class":6},{"name":78,"class":6},"Brighton & Sussex Medical School",{"name":57,"class":6},{"name":81,"class":6},"Radboud University Medical Center",{"name":83,"class":84},"Meningitis Foundation","UNKNOWN","100610453","phase-2-b-palmz-for-tb-meningitis-100610453",false,"NCT07227779","B-PaLMZ for TB Meningitis","A PHASE 2 NOVEL ANTIMICROBIAL COMBINATION THERAPY TO TREAT TUBERCULOUS MENINGITIS","Inclusion Criteria:\n\n* First Episode definite or probable TBM with physician intent to treat\n* Age ≥18 years\n* Provision of Informed Consent by participant or surrogate\n* Living with HIV\n* Weight \\> 35kg, estimate or measured\n\nExclusion Criteria:\n\n* Additional active and confirmed CNS infection\n* Known rifampicin-resistant TB\n* Allergy or contraindication to a study medicine\n* More than 5 doses of any TB therapy received within the previous 14 days\n* Presence of jaundice, known liver cirrhosis, elevated ALT or AST \\>3x ULN, or total bilirubin \\>2x ULN\n* Estimated Glomerular Filtration Rate \\\u003C30 ml\u002Fmin\u002F1.73m2\n* Significant cardiac comorbidity, heart failure, arrhythmia, or QTc \\>450 ms\n* Pregnancy or Breastfeeding\n* Cryptococcal antigen positivity in blood\n* Condition which makes participation not in the participant's best interest","ALL","18 Years",{"count":95,"type":96},240,"ESTIMATED","INTERVENTIONAL",[99],"PHASE2","This two-stage study will compare consented research participants with tuberculous meningitis receiving BPaLMZ to controls receiving SOC of rifampicin (R), isoniazid (H), pyrazinamide (Z), and ethambutol (E), known as RHZE.",[102,103,104,105],"Tuberculous Meningitis","HIV","Meningitis","TB - Tuberculosis","2026-07-28",{"date":108,"type":109},"2026-07-30","ACTUAL",{"date":106,"type":109},{"date":112,"type":96},"2030-09-30",{"name":71,"class":6},2]